Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to $290000.0.

  • Bolt Biotherapeutics' Depreciation & Amortization (CF) fell 3409.09% to $290000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 1975.85%. This contributed to the annual value of $1.8 million for FY2024, which is 393.74% down from last year.
  • Per Bolt Biotherapeutics' latest filing, its Depreciation & Amortization (CF) stood at $290000.0 for Q3 2025, which was down 3409.09% from $347000.0 recorded in Q2 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Depreciation & Amortization (CF) peaked at $467000.0 during Q1 2023, and registered a low of $256000.0 during Q2 2021.
  • Over the past 5 years, Bolt Biotherapeutics' median Depreciation & Amortization (CF) value was $426000.0 (recorded in 2024), while the average stood at $396315.8.
  • Per our database at Business Quant, Bolt Biotherapeutics' Depreciation & Amortization (CF) soared by 16930.69% in 2021 and then tumbled by 3409.09% in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' Depreciation & Amortization (CF) stood at $361000.0 in 2021, then increased by 27.98% to $462000.0 in 2022, then increased by 1.08% to $467000.0 in 2023, then dropped by 8.78% to $426000.0 in 2024, then crashed by 31.92% to $290000.0 in 2025.
  • Its last three reported values are $290000.0 in Q3 2025, $347000.0 for Q2 2025, and $399000.0 during Q1 2025.